- Home
- VMO vs CSTL Comparison
VMO vs CSTL Comparison
Compare VMO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMO
- CSTL
- Stock Information
- Founded
- VMO 1992
- CSTL 2007
- Country
- VMO United States
- CSTL United States
- Employees
- VMO N/A
- CSTL N/A
- Industry
- VMO Trusts Except Educational Religious and Charitable
- CSTL Medical Specialities
- Sector
- VMO Finance
- CSTL Health Care
- Exchange
- VMO Nasdaq
- CSTL Nasdaq
- Market Cap
- VMO 608.3M
- CSTL 697.9M
- IPO Year
- VMO N/A
- CSTL 2019
- Fundamental
- Price
- VMO $9.55
- CSTL $21.62
- Analyst Decision
- VMO
- CSTL Strong Buy
- Analyst Count
- VMO 0
- CSTL 6
- Target Price
- VMO N/A
- CSTL $37.67
- AVG Volume (30 Days)
- VMO 254.7K
- CSTL 423.4K
- Earning Date
- VMO 01-01-0001
- CSTL 11-03-2025
- Dividend Yield
- VMO 4.39%
- CSTL N/A
- EPS Growth
- VMO N/A
- CSTL N/A
- EPS
- VMO N/A
- CSTL N/A
- Revenue
- VMO N/A
- CSTL $346,269,000.00
- Revenue This Year
- VMO N/A
- CSTL N/A
- Revenue Next Year
- VMO N/A
- CSTL N/A
- P/E Ratio
- VMO N/A
- CSTL N/A
- Revenue Growth
- VMO N/A
- CSTL 20.40
- 52 Week Low
- VMO $7.86
- CSTL $14.59
- 52 Week High
- VMO $9.87
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- VMO 74.77
- CSTL 50.19
- Support Level
- VMO $9.47
- CSTL $22.54
- Resistance Level
- VMO $9.54
- CSTL $24.74
- Average True Range (ATR)
- VMO 0.06
- CSTL 1.14
- MACD
- VMO 0.03
- CSTL -0.28
- Stochastic Oscillator
- VMO 97.56
- CSTL 28.93
About VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.